Metabolic Latest News Archive

Heritability of BMI Stronger in Obesogenic Environments

Heritability of BMI Stronger in Obesogenic Environments

Heritability of BMI was significantly higher in children living in high-risk obesogenic environments compared with those living in low-risk environments.

High Variability in Metabolic Parameters May Predict All-Cause Mortality

High Variability in Metabolic Parameters May Predict All-Cause Mortality

High variability of fasting blood glucose and total cholesterol levels, systolic blood pressure, and BMI may be an independent predictor of cardiovascular events.

Significant Mortality Reduction With Empagliflozin in T2D and Established CVD

Significant Mortality Reduction With Empagliflozin in T2D and Established CVD

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

Atopic Dermatitis Likely Not Associated With Cardiometabolic Disease

Atopic Dermatitis Likely Not Associated With Cardiometabolic Disease

Atopic dermatitis was not found to be an independent risk factor for cardiometabolic disease in this meta-analysis.

Triglyceride-Lowering Alleles Associated With Reduced Coronary Artery Disease Risk

Triglyceride-Lowering Alleles Associated With Reduced Coronary Artery Disease Risk

Triglyceride-lowering variants in the lipoprotein lipase pathway are independently associated with protection from coronary artery disease and type 2 diabetes.

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Trends in Cardiovascular Deaths for US Adults With and Without Diabetes

Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.

Inflammation and Endothelial Stress Associated With CV Risk in Type 2 Diabetes With Manifest CVD

Inflammation and Endothelial Stress Associated With CV Risk in Type 2 Diabetes With Manifest CVD

The risk for cardiovascular events in patients with type 2 diabetes without manifest cardiovascular disease is primarily related to the severity of atherosclerosis.

Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline

Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline

While certain biomarkers are associated with eGFR decline in patients with type 2 diabetes, their predictive power is low.

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D

Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.

Results From Long-Term Cardiovascular Safety Study of Lorcaserin Announced

Results From Long-Term Cardiovascular Safety Study of Lorcaserin Announced

Approximately 12,000 patients took part in the CAMELLIA-TIMI 61 trial in which participants were randomized to either lorcaserin HCl 10mg twice daily or placebo.

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

Investigators examined the association between hypoglycemia and cardiovascular outcomes and death.

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Investigators examined the relationship between the use of β-blockers and incidence of hypoglycemia and risk for mortality in hospitalized patients with diabetes.

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.

Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes

Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes

Investigators sought to determine whether methylglyoxal levels are associated with cardiovascular disease in type 2 diabetes.

Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder

Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder

Patients with remitted bipolar disorder and emotional hyper-reactivity also have significantly higher levels of low-grade inflammation, hypertension, and impaired glucose metabolism, indicating a higher risk for cardiometabolic dysfunction.

Cardiovascular Mortality in Individuals With Early-, Late-Onset Prediabetes

Cardiovascular Mortality in Individuals With Early-, Late-Onset Prediabetes

Investigators examined the frequency of cardiovascular vs noncardiovascular deaths in individuals who developed prediabetes that did not progress to diabetes.

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.

Antipsychotics Increase Risk for Metabolic Syndrome, CVD in Younger Patients

Antipsychotics Increase Risk for Metabolic Syndrome, CVD in Younger Patients

Younger patients treated with antipsychotics after experiencing a first episode of psychosis are at an increased risk for metabolic syndrome and cardiovascular disease.

Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers

Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers

Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.

Canagliflozin Reduces CV Death and Hospitalizations for Heart Failure in T2D

Canagliflozin Reduces CV Death and Hospitalizations for Heart Failure in T2D

Patients with type 2 diabetes at risk for heart failure are particularly likely to benefit from treatment with canagliflozin.

ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes

ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes

The American Diabetes Association has updated its Clinical Standards of Medical Care guidelines for identifying and managing cardiovascular risk factors in diabetes.

HbA1c Levels Affect Serum Phospholipids, Inflammation in T2D, CVD

HbA1c Levels Affect Serum Phospholipids, Inflammation in T2D, CVD

Investigators sought to determine the association between serum phospholipid fatty acid composition, low-grade inflammation, and glycemic control in patients with T2D.

Low Sperm Count Associated With Worse Metabolic, Cardiovascular, and Bone Health

Low Sperm Count Associated With Worse Metabolic, Cardiovascular, and Bone Health

Researchers tested whether semen quality and reproductive function could be a marker of general health in men.

ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes

ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes

ACP responds to criticism from the ADA, the Endocrine Society, the AACE, and the AADE of guidance that clinicians should aim to achieve an HbA1c level between 7% and 8% in most people with type 2 diabetes.

Tresiba Label Updated With Data on Cardiovascular Outcomes

Tresiba Label Updated With Data on Cardiovascular Outcomes

The FDA has approved an update to the prescribing information for Tresiba to include cardiovascular outcomes and severe hypoglycemia study data.

T2D and Hypertriglyceridemia: No Cardiovascular Benefit With Fenofibrate or Statins

T2D and Hypertriglyceridemia: No Cardiovascular Benefit With Fenofibrate or Statins

Statins were associated with a reduction in mortality but there was no significant difference in the composite end point with fenofibrates alone or in combination with statins.

Reducing Total Daily Insulin Dose in T2D: 3-Meal vs 6-Meal Diet

Reducing Total Daily Insulin Dose in T2D: 3-Meal vs 6-Meal Diet

In people with obesity and type 2 diabetes, a meal schedule that includes a high-energy breakfast promotes weight loss, improves diabetes, and decreases the need for insulin.

ADA Responds to ACP Guidelines on Blood Glucose Targets in Type 2 Diabetes

ADA Responds to ACP Guidelines on Blood Glucose Targets in Type 2 Diabetes

The American Diabetes Association has responded with "deep" concern to recent hemoglobin A1c target guidance authored by the American College of Physicians.

Aortic Disease Risk May Be Attenuated by Type 2 Diabetes

Aortic Disease Risk May Be Attenuated by Type 2 Diabetes

T2D may play a protective role against the development of aortic diseases through structural changes in the aortic wall.

Expanded Use of TIMI Risk Score for CV Event Prediction in Diabetes

Expanded Use of TIMI Risk Score for CV Event Prediction in Diabetes

The expanded use of TIMI Risk Score for Secondary Prevention in patients with T2D may be helpful to predict risk for CV events accurately.

Cardiovascular Events and Mortality With GLP-1 Receptor Agonists

Cardiovascular Events and Mortality With GLP-1 Receptor Agonists

Glucagon-like peptide-1 receptor agonists can reduce major adverse cardiovascular events in patients with type 2 diabetes.

Semaglutide Approved for Adults With Type 2 Diabetes

Semaglutide Approved for Adults With Type 2 Diabetes

The FDA has approved semaglutide injection for the treatment of type 2 diabetes in adults.

Cardiovascular Outcomes With Insulin-Induced Weight Gain in T2D

Cardiovascular Outcomes With Insulin-Induced Weight Gain in T2D

Weight gain associated with insulin therapy is not associated with adverse cardiovascular outcomes in people with type 2 diabetes.

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

Evolocumab may decrease the risk for adverse cardiovascular events in patients with and without diabetes.

Insulin Initiation Associated With Weight Gain, Activity Decreases in T2D

Insulin Initiation Associated With Weight Gain, Activity Decreases in T2D

Initiation of insulin therapy in patients with type 2 diabetes was associated to inactivity and weight gain.

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

Patients with psoriasis have high rates of cardiometabolic comorbidities.

Diabetes Increases Hospital Readmissions Rates

Diabetes Increases Hospital Readmissions Rates

Patients with diabetes had a higher rate of readmission to hospitals compared with patients without diabetes.

FDA Tentatively Approves Follow-On Biologic Basal Insulin Glargine

FDA Tentatively Approves Follow-On Biologic Basal Insulin Glargine

Tentative FDA approval has been granted to Merck's follow-on biologic basal insulin injection, Lusduna Nexvue.

CVD Risk in Type 1 Diabetes Improved With Metformin

CVD Risk in Type 1 Diabetes Improved With Metformin

Metformin therapy in type 1 diabetes may improved cardiovascular disease risk management.

FDA to Review Insulin Degludec for Cardiovascular Safety

FDA to Review Insulin Degludec for Cardiovascular Safety

Novo Nordisk submitted an application to the FDA with data on the cardiovascular safety of an insulin degludec.

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

Cardiovascular Stress in Type 2 Diabetes Reduced With Canagliflozin

American Diabetes Association presented a study that Canagliflozin could possibly decrease cardiovascular stress in older patients with type 2 diabetes.

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

CV Risks in Obesity and Diabetes Not Increased With Nalxtrexone/Bupropion

Two studies found that extended-release naltrexone/bupropion did not increase cardiovascular risks for patients with type 2 diabetes.

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

Intensive Glucose Control in Diabetes Reduces Kidney and Eye Events

Kidney and eye events in type 2 diabetes were reduced with more intensive glucose control.

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.

Glucagon-Like Peptide-1 Receptor Agonists May Lower Cardiovascular Risk in Type 2 Diabetes

Glucagon-Like Peptide-1 Receptor Agonists May Lower Cardiovascular Risk in Type 2 Diabetes

Glucagon-like peptide-1 receptor agonist therapy was associated with lower risk for acute MI, stroke, and all-cause mortality.

Frequent Hot Flashes Give Cardiovascular Insight In Young Women

Frequent Hot Flashes Give Cardiovascular Insight In Young Women

Frequent hot flashes in younger women were linked to endothelial function, providing more insight into the cardiovascular disease risk status of patients.

Overweight/Obesity Affects Brain Function in Type 2 Diabetes

Overweight/Obesity Affects Brain Function in Type 2 Diabetes

Overweight or obese patients with type 2 diabetes mellitus are more likely to show severe and progressive brain function and cognition abnormalities.

Low HbA1c After Metformin Initiation Lowers CV Risks in T2D Patients

Low HbA1c After Metformin Initiation Lowers CV Risks in T2D Patients

A large, initial reduction in hemoglobin A1c (HbA1c) and achievement of low HbA1c levels 6 months after metformin initiation lowered the risk for cardiovascular events and death in patients with type 2 diabetes.

Severe Hypoglycemia Affects Short-Term Mortality in Type 2 Diabetes

Severe Hypoglycemia Affects Short-Term Mortality in Type 2 Diabetes

The majority of patients with diabetes requiring hospitalization for severe hypoglycemia were patients with type 2 diabetes.

Acute MI In-Hospital Mortality Rates in Type 2 Diabetes

Acute MI In-Hospital Mortality Rates in Type 2 Diabetes

Patients with type 1 diabetes admitted for acute myocardial infarction had higher mortality rates compared with patients with type 2 diabetes.

Effect of Avocados on Metabolic Syndrome Components

Effect of Avocados on Metabolic Syndrome Components

Avocado consumption most affected LDL, HDL, and total cholesterol, triglycerides, and phospholipids.

Stroke and MI Rates Have Decreased Since Trans Fatty Acid Restrictions Enacted

Stroke and MI Rates Have Decreased Since Trans Fatty Acid Restrictions Enacted

Compared with New York counties without trans fatty acid restrictions, those with restrictions showed a significantly greater decline in combined myocardial infarction and stroke events.

Lower HbA1c Post-PCI Promotes Better Outcomes in Diabetes

Lower HbA1c Post-PCI Promotes Better Outcomes in Diabetes

Patients with HbA1c levels had lower 7-year incidence of major adverse cardiac and cerebrovascular events compared with patients with higher HbA1c levels.

Cardiometabolic Comorbidities Found in Majority of Inpatients With Schizophrenia, Bipolar Disorder

Cardiometabolic Comorbidities Found in Majority of Inpatients With Schizophrenia, Bipolar Disorder

Study results emphasize the importance of identifying optimal treatment regimens for patients with serious mental illness.

Higher BMI Linked With Lower Mortality in Adult Congenital Heart Disease

Higher BMI Linked With Lower Mortality in Adult Congenital Heart Disease

Higher BMI was associated with lower all-cause and cardiac mortality in adults with congenital heart disease, even after adjusting for age, defect complexity, cyanosis, and objective exercise capacity.

Enteric-Coated Aspirin Therapy in Type 2 Diabetes and Obesity

Enteric-Coated Aspirin Therapy in Type 2 Diabetes and Obesity

Patients with obesity and type 2 diabetes were exposed to 3 different aspirin formulations.

FDA: Empagliflozin Can Reduce Risk for Cardiovascular Death

FDA: Empagliflozin Can Reduce Risk for Cardiovascular Death

In a postmarket trial of more than 7000 adults, empagliflozin was superior to placebo for reduction of cardiovascular death.

Prediabetes Risk Assessment Tool May Be Problematic

Prediabetes Risk Assessment Tool May Be Problematic

According to this risk assessment tool, the majority of US adults are considered high risk for prediabetes, though confirmation is required through medical visit and blood glucose test.

Abdominal Fat Quantity and Quality Changes Associated With Incident CVD Risk Factors

Abdominal Fat Quantity and Quality Changes Associated With Incident CVD Risk Factors

Changes in quantity and attenuation of abdominal fat affect changes in incident CVD and metabolic risk factors.

Sudden Cardiac Death Risk Linked to Higher Thyroid Levels

Sudden Cardiac Death Risk Linked to Higher Thyroid Levels

There was a hazard ratio of 1.87 per 1-ng/dL increase of free thyroxine for patients with an increased risk of sudden cardiac death due to higher free thyroxine levels.

AHA Calls for Guidelines on Sleep Disorders and CV Risk

AHA Calls for Guidelines on Sleep Disorders and CV Risk

An AHA panel recommended developing guidelines on adequate sleep and suggestions on how to include sleep disorder screenings in routine health care and public health settings.

Internet and Mobile Interventions Aid in Lifestyle Behavior Modifications

Internet and Mobile Interventions Aid in Lifestyle Behavior Modifications

Information technology interventions were successful in studies evaluating changes in diet, tobacco and alcohol use, and physical activity.

Adverse LV Remodeling and Dysfunction Affected by Diabetes and Insulin Resistance

Adverse LV Remodeling and Dysfunction Affected by Diabetes and Insulin Resistance

The group who developed diabetes earlier had less favorable left ventricular ejection fraction, 4-chamber longitudinal peak strain, and circumferential peak strain.

Metabolic Syndrome Severity May Be Tied to Menopausal Transition

Metabolic Syndrome Severity May Be Tied to Menopausal Transition

African-American women in particular experienced more rapid progression in metabolic syndrome severity during pre- and peri-menopausal periods compared to post-menopausal period.

Liraglutide Lowered Cardiovascular Event Rates in Type 2 Diabetes

Liraglutide Lowered Cardiovascular Event Rates in Type 2 Diabetes

LEADER trial results demonstrated that liraglutide lowered first occurrence of death from cardiovascular causes in patients with type 2 diabetes.

Prior Cardiovascular Event Increased Mortality for Type 2 Diabetes Patients

Prior Cardiovascular Event Increased Mortality for Type 2 Diabetes Patients

Heart failure is a particularly powerful predictor of mortality in patients who have both coronary heart disease and type 2 diabetes.

Higher Body Mass Index in Adolescence Associated With Increased Risk of Mortality

Higher Body Mass Index in Adolescence Associated With Increased Risk of Mortality

The obese group compared with the group in 5th to 24th BMI percentiles had higher hazard ratios for death from coronary heart disease, stroke, sudden death, and total cardiovascular causes.

High-Fat, High-Caloric Foods May Be Less Desirable With Liraglutide

High-Fat, High-Caloric Foods May Be Less Desirable With Liraglutide

Liraglutide decreased desirability of high-fat, high-caloric foods, which could lead to the drug being used as weight loss therapy.

More Statin Use Among Patients of Puerto Rican and Dominican Backgrounds

More Statin Use Among Patients of Puerto Rican and Dominican Backgrounds

In patients who were at high risk for cardiovascular disease, 25% of those from Puerto Rican and Dominican backgrounds used statins and less than half used aspirin.

Cycling, Walking, and Public Transit Use Linked to Lower BMI

Cycling, Walking, and Public Transit Use Linked to Lower BMI

Individuals who used active modes of transport, walking, cycling, as well as mixing walking and cycling with public transit had significantly lower BMI and percentage body fat compared with sedentary car users.

American Heart Association Ideal Cardiovascular Health Factors Associated With Cognitive Function

American Heart Association Ideal Cardiovascular Health Factors Associated With Cognitive Function

Ideal BMI, lack of smoking, and ideal fasting glucose were the 3 cardiovascular health factors most strongly associated with greater processing speed performance.

Statins: Beyond Treatment for Low-Density Lipoprotein Cholesterol

Statins: Beyond Treatment for Low-Density Lipoprotein Cholesterol

In metabolomic profiling study, statins were found to affect more extensive lipid changes beyond low-density lipoprotein cholesterol.

Apixaban Associated With Lower Risk for Stroke Than Aspirin in Patients With AF and Low-Risk Stroke Classification

Apixaban Associated With Lower Risk for Stroke Than Aspirin in Patients With AF and Low-Risk Stroke Classification

The anticoagulant apixaban was found to increase life expectancy at a higher rate than aspirin in patients with low risk for stroke.

Replacing Saturated Fats and Sugary Carbohydrates With Unsaturated Fats Reduces Risk of Coronary Heart Disease

Replacing Saturated Fats and Sugary Carbohydrates With Unsaturated Fats Reduces Risk of Coronary Heart Disease

Replacing saturated fats and sugary carbohydrates with unsaturated fats reduces the risk of coronary heart disease.

Interrupting Sedentary Behaviors May Have Cardiometabolic Benefits for Kids

Interrupting Sedentary Behaviors May Have Cardiometabolic Benefits for Kids

Interrupting long periods of sedentary behavior with short walks could reduce cardiometabolic risk in children.

Sitagliptin Does Not Increase Risk for Cardiovascular Events, Heart Failure

Sitagliptin Does Not Increase Risk for Cardiovascular Events, Heart Failure

Sitagliptin did not affect rates of cardiovascular complications or heart failure in high-risk patients with type 2 diabetes.

Sign Up for Free e-Newsletters